China Blood Products Market Increases Steadily, Driven By Increased Price And Government's Stricter Supervision
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The sale of blood products in China reached $3.966 billion in 2008 with an annual growth rate 12.23 percent, according to consulting company Draco Healthcare. The growth will continue in the future, driven by increasing demand, limited supply and higher prices
You may also be interested in...
Vaccine Market Will Lead Pharmaceutical Industry In China And Globally, Frost & Sullivan Predicts
SHANGHAI - The compound annual growth rate of the global pharmaceutical industry is expected to be around 4-5 percent in the next seven years, while the worldwide vaccine market grows faster, at a CAGR of 14-15 percent, the global business research and consulting firm Frost & Sullivan predicted
China Biologic Opens New Plasma Collection Station As China’s Blood Product Reforms Have Closed Doors For Many Competitors
SHANGHAI - China Biologic Products began operations at its new plasma collection station in Qihe County, Shandong Province, the company announced July 9, increasing its annual supply of plasma from 60 to 80 metric tons to 100 metric tons
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).